Clinical trials
Esophageal Squamous Cell Cancer clinical trials
Below are recruiting esophageal squamous cell cancer clinical trials, each written for real people, not researchers. We’re tracking 261 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05515315RecruitingPhase 2
Immunotherapy plus chemo then chemoradiation for esophageal cancer
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
Fuzhou, FujianAges 18–70 - NCT07863141RecruitingPhase 2
Maintenance therapy after first-line chemoimmunotherapy for advanced esophageal cancer
This study compares two maintenance treatments after initial chemotherapy plus immunotherapy for advanced esophageal squamous cell carcinoma. The goal is to see if adding anlotinib, a targeted drug that blocks blood vessel growth to tumors, to a PD-1 inhibitor is more effective than the PD-1 inhibitor alone.
Guangzhou, GuangdongAges 18–75 - NCT07858630Recruiting
Radiation targeting for advanced esophageal cancer with immunotherapy
This trial studies how to best target radiation for people with advanced esophageal cancer who are also getting immunotherapy. It aims to improve treatment planning to help patients live longer with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06194734RecruitingPhase 3
KC1036 vs. chemo for advanced esophageal cancer
This study compares a new drug, KC1036, to standard chemotherapy options for people with advanced esophageal squamous cell cancer that has progressed after immunotherapy and at least one chemo. It aims to see if KC1036 works better or has fewer side effects.
BeijingAges 18–75 - NCT06187597RecruitingPhase 2
Toripalimab after chemoradiation for older esophageal cancer
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Guangzhou, GuangdongAges 70–85 - NCT06304350RecruitingPhase 2
Pembrolizumab plus chemo before surgery for esophageal cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06383728RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutated lung cancer
This trial tests if taking a targeted therapy drug before surgery can help shrink tumors in people with a specific type of lung cancer called EGFR-mutated squamous cell carcinoma that can be removed with surgery. The goal is to see if this approach improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06410651RecruitingPhase 2
Nimotuzumab with chemoradiation for advanced esophageal cancer
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
BeijingAges 18–80 - NCT06429839RecruitingPhase 2
Nimotuzumab with chemoradiation for esophageal cancer
This trial tests a drug called nimotuzumab combined with standard chemotherapy and radiation for patients with esophageal cancer. It may help improve treatment effectiveness for those whose cancer has not spread to other parts of the body.
BeijingAges 18–80 - NCT06463834RecruitingPhase 2
Sintilimab plus chemo before surgery for esophageal cancer
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Fuzhou, FujianAges 18–75 - NCT06385730RecruitingPhase 2
PD-1 blocker before surgery for elderly esophageal cancer
This trial tests a drug (PD-1 blocker) given before surgery for people over 75 with esophageal cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 76 years+ - NCT07814248RecruitingPhase 1
TS-104 for advanced solid tumors
This trial tests a new drug called TS-104 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is given alone (not with other cancer treatments) to see if it can shrink tumors or slow their growth.
Maumee, OhioAges 18 years+ - NCT07812805RecruitingPhase 1
New targeted treatment with imaging for advanced solid tumors
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Glen Burnie, MarylandAges 18 years+ - NCT07811752RecruitingPhase 2
Combination treatment for advanced esophageal cancer
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
ShanghaiAges 18 years+ - NCT06413342RecruitingPhase 2
Sintilimab after chemoradiation for older adults with esophageal cancer
This trial tests whether the immunotherapy drug Sintilimab can help prevent esophageal cancer from returning after standard chemotherapy and radiation. It is for patients aged 70-85 who cannot have or choose not to have surgery.
Hangzhou, ZhejiangAges 70–85 - NCT06138028RecruitingPhase 2/Phase 3
Sintilimab plus chemo and radiation for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy followed by radiation therapy for advanced esophageal cancer that has spread. The goal is to see if this sequence can help shrink tumors and improve outcomes.
Qingdao, ShandongAges 18–80 - NCT04481256Recruiting
Immunotherapy with chemoradiation for esophageal cancer
This trial tests adding medicines that block TGF-beta and PD-L1 to standard chemoradiation for esophageal squamous cell cancer that can’t be removed with surgery. It aims to improve control of the cancer where it sits, while keeping treatment safe.
AmsterdamAges 18 years+ - NCT07787273RecruitingPhase 2
Combination therapy before surgery for esophageal cancer
This trial tests a combination of two drugs (interferon gamma and camrelizumab) given before surgery for a certain type of esophageal cancer. It aims to see if this combination can shrink the tumor and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT07770100RecruitingPhase 2
Matching immunotherapy and targeted radiation for advanced cancer
This trial tests combining immunotherapy (a treatment that boosts your immune system to fight cancer) with a targeted type of radiation called SBRT, which precisely delivers high-dose radiation to multiple cancer spots. The main goal is to see if this combination helps control metastatic cancer (cancer that has spread) better than standard care.
Lexington, KentuckyAges 18–99 - NCT07751055RecruitingPhase 2
Chemotherapy and radiation with immunotherapy before surgery for esophageal cancer
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
Guangzhou, GuangdongAges 18–75 - NCT07751341RecruitingPhase 2
New drug with chemotherapy for advanced esophageal cancer
This study tests a new drug (SHR-9839) alone or combined with standard chemotherapy and another immunotherapy drug (adebrelimab) for advanced esophageal cancer. The goal is to see if this combination helps shrink tumors or slow cancer growth better than the standard treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT05495152RecruitingPhase 3
Sintilimab after esophageal surgery to help prevent cancer return
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
Zhengzhou, HenanAges 18–70 - NCT07700667RecruitingPhase 2
Testing a new drug combo for advanced esophageal cancer
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
ChangchunAges 18–75 - NCT06646588RecruitingPhase 2
Study of fruquintinib, tislelizumab, and radiation for esophageal cancer
This trial tests a combination of two drugs (fruquintinib and tislelizumab) followed by radiation therapy for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach can help shrink tumors and improve outcomes.
Shijiazhuang, HebeiAges 18 years+
Hear when a new Esophageal Squamous Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for esophageal squamous cell cancer?
- Yes. Clin2 currently lists 261 recruiting esophageal squamous cell cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a esophageal squamous cell cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a esophageal squamous cell cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.